Publications by authors named "M Pieniazek"

Article Synopsis
  • Palliative care for patients with hormone receptor-positive, HER2-negative advanced breast cancer should be individualized, especially regarding when to stop treatment, as evidenced by a study assessing the time between last oncologist visit and death.
  • The study involved 76 women, with a median age of about 63, who had received multiple lines of palliative treatment; surprisingly, 75% were still on active treatment during their last oncologist visit.
  • Findings indicated a median of 23 days from the last visit to death, with the timing of ceasing systemic therapy often delayed, highlighting the need for improved end-of-life care guidelines and training for healthcare providers.
View Article and Find Full Text PDF

Gesture recognition has become a significant part of human-machine interaction, particularly when verbal interaction is not feasible. The rapid development of biomedical sensing and machine learning algorithms, including electromyography (EMG) and convolutional neural networks (CNNs), has enabled the interpretation of sign languages, including the Polish Sign Language, based on EMG signals. The objective was to classify the game control gestures and Polish Sign Language gestures recorded specifically for this study using two different data acquisition systems: BIOPAC MP36 and MyoWare 2.

View Article and Find Full Text PDF

In the evolving field of human-computer interaction (HCI), gesture recognition has emerged as a critical focus, with smart gloves equipped with sensors playing one of the most important roles. Despite the significance of dynamic gesture recognition, most research on data gloves has concentrated on static gestures, with only a small percentage addressing dynamic gestures or both. This study explores the development of a low-cost smart glove prototype designed to capture and classify dynamic hand gestures for game control and presents a prototype of data gloves equipped with five flex sensors, five force sensors, and one inertial measurement unit (IMU) sensor.

View Article and Find Full Text PDF

Introduction: Sacituzumab govitecan (SG) is approved for patients with previously treated metastatic or locally advanced triple-negative breast cancer (TNBC), as per the ASCENT trial results. Real-world studies (RWSs) cover more diverse patients than clinical trials, offering crucial data for healthcare policies. This study aimed to investigate the safety and efficacy of SG in real-world Polish patients with previously treated metastatic TNBC.

View Article and Find Full Text PDF

Background And Purpose: Metaplastic breast carcinoma (BC-Mp) is an uncommon subtype that poses unique challenges. The limited information on patient prognosis and therapeutic strategies motivated our research initiative. We aimed to assess disease-free survival (DFS), overall survival (OS), and influential factors in patients with nonmetastatic BC-Mp.

View Article and Find Full Text PDF